Annexin 2A Sustains Glioblastoma Cell Dissemination and Proliferation
Overview
Authors
Affiliations
Glioblastoma (GBM) is the most devastating tumor of the brain, characterized by an almost inevitable tendency to recur after intensive treatments and a fatal prognosis. Indeed, despite recent technical improvements in GBM surgery, the complete eradication of cancer cell disseminated outside the tumor mass still remains a crucial issue for glioma patients management. In this context, Annexin 2A (ANXA2) is a phospholipid-binding protein expressed in a variety of cell types, whose expression has been recently associated with cell dissemination and metastasis in many cancer types, thus making ANXA2 an attractive putative regulator of cell invasion also in GBM.Here we show that ANXA2 is over-expressed in GBM and positively correlates with tumor aggressiveness and patient survival. In particular, we associate the expression of ANXA2 to a mesenchymal and metastatic phenotype of GBM tumors. Moreover, we functionally characterized the effects exerted by ANXA2 inhibition in primary GBM cultures, demonstrating its ability to sustain cell migration, matrix invasion, cytoskeletal remodeling and proliferation. Finally, we were able to generate an ANXA2-dependent gene signature with a significant prognostic potential in different cohorts of solid tumor patients, including GBM.In conclusion, we demonstrate that ANXA2 acts at multiple levels in determining the disseminating and aggressive behaviour of GBM cells, thus proving its potential as a possible target and strong prognostic factor in the future management of GBM patients.
QSOX1 Modulates Glioblastoma Cell Proliferation and Migration In Vitro and Invasion In Vivo.
Dutt R, Thorpe C, Galileo D Cancers (Basel). 2024; 16(21).
PMID: 39518060 PMC: 11545231. DOI: 10.3390/cancers16213620.
Balboni A, Ailuno G, Baldassari S, Drava G, Petretto A, Grinovero N Sci Rep. 2024; 14(1):19225.
PMID: 39160236 PMC: 11333626. DOI: 10.1038/s41598-024-69696-7.
The role of annexins in central nervous system development and disease.
White 2nd Z, Nair S, Bredel M J Mol Med (Berl). 2024; 102(6):751-760.
PMID: 38639785 PMC: 11106189. DOI: 10.1007/s00109-024-02443-7.
Glioblastoma Therapy: Past, Present and Future.
Obrador E, Moreno-Murciano P, Oriol-Caballo M, Lopez-Blanch R, Pineda B, Gutierrez-Arroyo J Int J Mol Sci. 2024; 25(5).
PMID: 38473776 PMC: 10931797. DOI: 10.3390/ijms25052529.
Grindheim A, Patil S, Nebigil C, Desaubry L, Vedeler A Front Cell Dev Biol. 2023; 11:1094941.
PMID: 37250892 PMC: 10214161. DOI: 10.3389/fcell.2023.1094941.